Price Alert

Xenetic Biosciences Inc. (XBIO)

NASDAQ: XBIO · Real-Time Price · USD

2.94

0.08 (2.80%)

At close: Aug 18, 2025, 3:47 PM

2.88

-1.74%

After-hours: Aug 18, 2025, 04:07 PM EDT

2.80% (1D)

Bid	2.8
Market Cap	4.53M
Revenue (ttm)	2.58M
Net Income (ttm)	-3.67M
EPS (ttm)	-2
PE Ratio (ttm)	-1.47
Forward PE	-0.63
Analyst	n/a

Ask	3
Volume	5,755
Avg. Volume (20D)	78,679
Open	2.86
Previous Close	2.86
Day's Range	2.86 - 2.99
52-Week Range	2.20 - 5.27
Beta	2.33

About XBIO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol XBIO

Website n/a

Full Company Profile

Earnings Surprise

Xenetic Biosciences has released their quartely earnings on Aug 13, 2025:

Revenue of $589.9K exceeds estimates by $44.7K, with -18.79% YoY decline.

EPS of -0.45 exceeds estimates by 0.19, with 45.78% YoY growth.

Next Earnings Release

Xenetic Biosciences Inc. is scheduled to release its earnings on Nov 11, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

News

6 days ago · accessnewswire.com

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies Ended the qu...

1 week ago · zacks.com

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.83 per share a year ago.

2 weeks ago · accessnewswire.com

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. ...

3 weeks ago · accessnewswire.com

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2...

1 month ago · accessnewswire.com

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess Company evaluating systemic recombinant human DNase I (DNase I) i...